Cargando…
PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
Great efforts have been made in dosimetry for individualizing PRRT. However, many centers do not use dosimetry and its results hardly influence treatment. A reason for that is that reliable thresholds for organs-at-risk, kidneys and bone marrow, and treatment response are lacking. The nuclear medici...
Autor principal: | Haug, Alexander R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158965/ https://www.ncbi.nlm.nih.gov/pubmed/32296955 http://dx.doi.org/10.1186/s13550-020-00623-3 |
Ejemplares similares
-
Long-term prognostic factors for PRRT in neuroendocrine tumors
por: Trautwein, Nils Florian, et al.
Publicado: (2023) -
Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
por: Rudisile, S., et al.
Publicado: (2019) -
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
por: Harris, Philip E., et al.
Publicado: (2022) -
Personalized radiation dosimetry for PRRT—how many scans are really required?
por: Freedman, Nanette, et al.
Publicado: (2020) -
Peptide Receptor Radionuclide Therapy (PRRT) with (177)Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
por: Jahn, Ulrika, et al.
Publicado: (2021)